ACC 2023 | COORDINATE-DIABETES

Approximately only 2.7% of all diabetic patients with ischemic heart disease in the United States receive optimal treatment consisting in high doses of statins (ACEI/ARAII) or “cardio-stable” antihyperglycemic agents such as SGLT2I and GLP-1RA (three of them). Of the population, 37.4% does not use any medication.

Randomization was conducted at the healthcare facility level, rather than at the patient level. Multifaceted intervention (identification of barriers, coping strategies, and subsequent feedback) was performed in 20 clinics and standard guidelines-based treatment in 23 sites. The study enrolled diabetic patients with atherosclerotic disease.

The primary endpoint was the prescription of all recommended treatment groups (atorvastatin 80 mg, ACEI/ARAII, antihyperglycemic with cardioprotective effect such as SGLT2I or GLP-1RA). At the 12-month follow-up, there was a significant absolute difference of 23.4% compared with treatment according to guidelines, with an unadjusted odds ratio of 4.46 (2.55-7.80; p ≤ 0.001).

The multifaceted strategy is effective in improving indications, which would lead to improved quality of care.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: “Coordinating Cardiology Clinics Randomized Trial Of Interventions To Improve Outcomes (COORDINATE) – Diabetes: Primary Results”.

Reference: Presentado por Neha Pagidipati en Late Breaking Trials del ACC.23/WCC Marzo 4-6, 2023, en New Orleans.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Direct Oral Anticoagulants for Ventricular Thrombus After STEMI

While the incidence of intracavitary thrombi after acute myocardial infarction (AMI) has decreased thanks to optimized primary angioplasty times, some studies report rates of...

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RODIN-CUT: Successive Cutting Balloon Technique in Calcified Lesions

Moderate or severe coronary calcification can be a marker of poor prognosis in coronary artery disease, as it significantly increases the risk of failure...

Acute Coronary Syndrome with Multivessel Disease: Best Revascularization Strategy

The gold standard treatment for acute coronary syndrome (ACS), especially acute myocardial infarction (AMI) is primary angioplasty (PCI). However, 40 to 70% of ACS...

Improved Ejection Fraction in Chronic Total Occlusion?

Chronic total occlusions (CTO) represent a significant challenge in the current clinical practice, seeing as CTO percutaneous coronary intervention (PCI) is complex and involves...